Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00095342 | Study Evaluating TMI-005 in Active Rheumatoid Arthritis | PHASE2 | COMPLETED | 390 | — | — | - | Aug 1, 2005 | Sep 10, 2009 | 8 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| TMI-005 | DRUG | - |
Inclusion Criteria: * Meet American College of Rheumatology (ACR) criteria for RA * Have active RA * Disease duration of at least 6 months * Disease onset at \> 16 years of age. Exclusion Criteria: * Any prior use of anti-TNF alpha biologics, rituximab, receipt of anti-CD4 or diphtheria interleuk...